Your browser doesn't support JavaScript. Please upgrade to a modern browser or enable JavaScript in your existing browser.
Skip Navigation U.S. Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
Archive print banner

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Table 1. Descriptive features and effect sizes of included studies

Study (Jadad
40 score*)
No. completed/
enrolled
Screening methods/
Screening timing
(weeks' gestation)
PTD
<37 weeks
PTD
<34 weeks
PTD
<32 weeks
PPROM LBW
<2500 g
ARR (90% CI)**
Average-risk women
McGregor30 (3) 129/142 Gram stain +
Amsel (16 to 27)
-0.077
(-0.169 to 0.014)
    -0.006
(-0.068 to 0.056)
-0.092
(-0.176 to 0.008)
Joesoef31 (4) 681/745 Gram stain (14 to 26) -0.015
(-0.059 to 0.029)
  -0.021
(-0.044 to 0.003)
  -0.021
(-0.056 to 0.012)
McDonald38 (4) 480/480 Gram stain (16 to 26)      

0.0017
(-0.010 to 0.044)

-0.003
(-0.034 to 0.027)

Carey39 (5) 1919/1953 Gram stain (16 to 23) 0.030
(-0.021 to 0.028)
  0.004
(-0.008 to 0.016)
-0.014
(-0.028 to 0.000)
0.005
(-0.019 to 0.029)
High-risk women
Morales36 (4) 80/94 Amsel (13 to 20) 0.263 (0.096 to 0.429) 0.066
(-0.035 to 0.166)
  0.288
(0.149 to 0.427)
0.197 (0.042 to 0.362)
Hauth37 (4) 177/177 Amsel (<24) 0.183 (0.052 to 0.314)        
McDonald38 (4) 34/34 Gram stain (16 to 26) 0.294 (0.082 to 0.507) 0.118
(-0.061 to 0.296)
  0.176
(0.024 to 0.329)
0.235 (0.005 to 0.465)
Carey39 (5) 210/213 Gram stain (16 to 23) -0.075
(-0.189 to 0.039)
0.012
(-0.055 to 0.078)
  -0.036
(-0.101 to 0.030)
-0.040
(-0.137 to 0.057)
Vermeulen35 (4) 22/22 Gram stain (26) 0.000
(-0.202 to 0.202)
     
*Measures quality of randomized controlled trials on a 5-point scale.
**Negative value indicates that outcome was more common in treated group than in controls (i.e., adverse effect of treatment).
PTD, preterm delivery; PPROM, preterm premature rupture of membranes; LBW, low birth weight; ARR, absolute risk reduction; CI, confidence interval.

Return to Document

 

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care